DURHAM, N.C. and NEW YORK, March 4,
2022 /PRNewswire/ -- Aerami Therapeutics Holdings, Inc.
("Aerami"), a biopharmaceutical company focused on developing
inhaled therapies to treat severe respiratory and chronic diseases,
and FoxWayne Enterprises Acquisition Corp. (NASDAQ: FOXW)
("FoxWayne"), a publicly traded special purpose acquisition company
("SPAC"), announced today that they have mutually agreed to
terminate their previously announced business combination
agreement, effective immediately.
In light of current unfavorable market conditions, Aerami and
FoxWayne believe that terminating the business combination
agreement is the best path forward for the parties and their
respective stockholders.
FoxWayne has until April 22, 2022
to complete an initial business combination (unless such date
is extended in accordance with FoxWayne's governing documents).
About Aerami
Aerami is a clinical stage biopharmaceutical company developing
inhaled therapies to treat severe respiratory and chronic diseases.
Aerami's lead development program is AER-901, a drug-device
combination product candidate in Phase 1 for the treatment of
pulmonary arterial hypertension. AER-901 is designed to improve
drug uptake and deliver consistent, therapeutically effective, and
well tolerated levels of a nebulized formulation of imatinib
through once-a-day inhalation via the FOX® device,
which is both 510(k) cleared and CE marked and which the Company
has licensed from Vectura Limited.
About FoxWayne
FoxWayne is a blank check company formed for the purpose of
effecting a merger, capital stock exchange, asset acquisition,
stock purchase, reorganization, or similar business combination
with one or more businesses. FoxWayne is led by Chairman and Chief
Executive Officer, Robb Knie.
Aerami Investor Contact:
CORE IR
Tel: 516-222-2560
investors@aerami.com
Aerami Media Contact:
Jules
Abraham
CORE IR
Tel: 917-885-7378
julesa@coreir.com
FoxWayne Investor Contact:
Investor Relations
Tel: 917-284-8938
investors@foxwayne.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/aerami-therapeutics-holdings-inc-and-foxwayne-enterprises-acquisition-corp-mutually-agree-to-terminate-business-combination-agreement-301496112.html
SOURCE FoxWayne Enterprises Acquisition Corp